Ambryon Biosciences

Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients

Phase 2 single-arm ELIANA trial of tisagenlecleucel (CTL019), an autologous anti-CD19 CAR T-cell product, in 79 children and young adults with relapsed or refractory B-cell ALL. 82% (65 of 79) achieved remission within 3 months, meeting the primary endpoint.

StatusCompleted
PhasePhase 2
Primary Endpoint ResultMet
Enrollment80
Start Date2015-04-08
Primary Completion Date2020-01-21

Results Summary

In the registry final results for the 79 infused patients, overall remission (CR or CRi within 3 months, independent review) was 82.3% (65 of 79; 95% CI 72.1-90.0) against a null of 20% (p<0.0001); 81.0% were MRD-negative. Remission was 96.0% (24 of 25) with baseline marrow blasts below 50% and 75.9% (41 of 54) at 50% or more. In the primary analysis (Maude 2018, n=75), remission was 81%, 12-month event-free and overall survival 50% and 76%; cytokine release syndrome (CRS) occurred in 77% (grade 4 in 25%), neurologic events in 40% (grade 3 in 13%, no cerebral edema), and grade 3 or 4 treatment-related events in 73%. At 5 years (median follow-up 79.4 months), relapse-free survival in 70 responders was 47.3% and overall survival 55.0% (censored at transplant or new therapy); 18 of 33 relapses were CD19-negative. Registry serious events: 63 of 79; CRS serious in 50 of 79 (non-serious in 37 of 79); 33 of 79 died.

Design Implications

A single infusion of autologous 4-1BB CD19 CAR T cells can be definitive therapy in multiply relapsed pediatric B-ALL: about half of responders were relapse-free at 5 years (47.3% or 51.0%, with or without censoring at transplant) and 53 of 70 had no post-infusion transplant, so CAR-T need not be a bridge to transplant. CD19 loss caused most relapses with known status (18 of 33 at 5 years), so single-antigen CARs face antigen escape; dual-antigen targeting is the next step. Response fell with high marrow blast burden (75.9% vs 96.0%), which supports treating at lower disease burden. Expansion did not depend on dose, but post hoc 5-year relapse-free survival was higher above the median dose, so a dose effect on durability is open. Early B-cell recovery (within 6 months) was linked to shorter remission, so B-cell aplasia reads out persistence, at the cost of hypogammaglobulinemia. CRS and neurologic events need a management protocol and ICU access. Product failure affected 7 of 92 enrolled.

Rationale

Tisagenlecleucel (CTL019) is made from the patient's own T cells, collected by leukapheresis and transduced ex vivo with a lentiviral vector to express a chimeric antigen receptor (CAR) that binds CD19 and carries CD3-zeta (activation) and 4-1BB (costimulation) domains. CD19 is expressed on B-cell acute lymphoblastic leukemia (B-ALL) blasts and is restricted to the B-cell lineage, so CD19-directed T cells were expected to kill leukemia that had relapsed after or resisted chemotherapy or allogeneic stem cell transplant. A single infusion after lymphodepleting chemotherapy was expected to expand and persist, giving continued control of residual leukemia.

Limitations

Single-arm, open-label phase 2 with no concurrent control; remission was tested against a historical null of 20%. 18 of 98 enrolled patients were never infused and efficacy covers infused patients only (intention-to-treat remission 66% in the primary analysis). Long-term survival depends on censoring for transplant and new therapy. Dose and B-cell recovery analyses are post hoc in small subgroups. Cohorts 1 (1 patient) and 2 (none) stopped for poor recruitment.

Registry record

This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 in pediatric patients with r/r B-cell ALL.

Primary OutcomesPercentage of Participants With Overall Remission Rate (ORR) as Determined by Independent Review Committee (IRC) Assessment.
KeywordsPediatric, ALL, Cell therapy, Lymphoblastic Leukemia, Acute, High Risk, Childhood, CTL019, tisagenlecleucel, Pediatric patients, r/r B-cell ALL, high risk B-cell ALL at first relapse, high risk B-cell ALL that relapsed < 6 months post allo-HSCT
Registry Last Updated2024-02-13
Results First Posted Date2021-11-22
Modalitiescell_therapy
Maximum Age25 Years
Intervention NamesCTL019
AllocationNot Applicable
MaskingNone
Primary PurposeTreatment
Has ResultsYes
AcronymELIANA
Enrollment TypeActual
CountriesUnited States, Australia, Austria, Belgium, Canada, France, Germany, Italy, Japan, Norway, Spain
Intervention Typesbiological
Study TypeInterventional
Intervention ModelSingle Group
Healthy VolunteersNo
Condition TermsB-cell Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Completion Date2022-11-17
Lead Sponsor ClassIndustry
Eligibility SexAll

Official Title

A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia

Eligibility Criteria

Inclusion Criteria:

  1. Relapsed or refractory pediatric B-cell ALL

  2. Adequate organ function

  3. For relapsed patients, documentation of CD19 tumor expression within 3 months of study entry.

  4. Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening.

  5. Life expectancy > 12 weeks.

  6. Karnofsky (age ≥16 years) or Lansky (age < 16 years) performance status ≥ 50 at screening

  7. Signed written informed consent and assent forms

  8. Must meet the institutional criteria to undergo leukapheresis or have an acceptable, store leukapheresis product

  9. Must have an apheresis product of non-mobilized cells received and accepted by the manufacturing site.

  10. Cohort 1 only:

    1. First relapse AND hypodiploid cytogenetics OR
    2. First relapse AND t(17;19) with defined TCF3-HLF fusion OR
    3. First relapse with any cytogenetics provided the relapse occurred ≤ 36 months of initial diagnosis AND MRD at end of reinduction therapy is ≥0.01% by flow cytometry (local assessment)

Exclusion Criteria

  1. Isolated extra-medullary disease relapse
  2. Patients with concomitant genetic syndrome: such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome or any other known bone marrow failure syndrome. Patients with Down Syndrome will not be excluded.
  3. Patients with Burkitt's lymphoma/leukemia (i.e. patients with mature B-cell ALL, leukemia with B-cell [sIg positive and kappa or lambda restricted positivity] ALL, with FAB L3 morphology and /or a MYC translocation)
  4. Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative intent and with no evidence of active disease
  5. Treatment with any prior gene therapy product
  6. Has had treatment with any prior anti-CD19/anti-CD3 therapy, or any other anti-CD19 therapy
  7. Active or latent hepatitis B or active hepatitis C (test within 8 weeks of screening), or any uncontrolled infection at screening
  8. Human Immunodeficiency Virus (HIV) positive test within 8 weeks of screening
  9. Presence of grade 2 to 4 acute or extensive chronic graft-versus-host disease (GVHD).
  10. Active CNS involvement by malignancy, defined by CNS-3 per NCCN guidelines.
  11. Patient has an investigational medicinal product within the last 30 days prior to screening.
  12. Pregnant or nursing (lactating) women.
  13. Women of child-bearing potential, defined as physiologically capable of becoming pregnant, unless they agree to use highly effective methods of contraception for at least 12 months after the CTL019 infusion and after CAR T-cells are no longer present by qPCR on two consecutive tests
  14. Sexually active males must use a condom during intercourse at least 12 months after the CTL019 infusion after CAR T-cells are no longer present by qPCR on two consecutive tests

Identifiers & revision